175 related articles for article (PubMed ID: 21951301)
1. Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Takata H; Takeda Y; Zhu A; Cheng Y; Yoneda T; Demura M; Yagi K; Karashima S; Yamagishi M
Diabetes Obes Metab; 2012 Feb; 14(2):155-62. PubMed ID: 21951301
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Hofni A; El-Moselhy MA; Taye A; Khalifa MM
Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Guo C; Martinez-Vasquez D; Mendez GP; Toniolo MF; Yao TM; Oestreicher EM; Kikuchi T; Lapointe N; Pojoga L; Williams GH; Ricchiuti V; Adler GK
Endocrinology; 2006 Nov; 147(11):5363-73. PubMed ID: 16901964
[TBL] [Abstract][Full Text] [Related]
5. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
6. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Gabor A; Leenen FH
Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
[TBL] [Abstract][Full Text] [Related]
7. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
[TBL] [Abstract][Full Text] [Related]
8. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Kobayashi N; Fukushima H; Takeshima H; Koguchi W; Mamada Y; Hirata H; Machida Y; Suzuki N; Yokotsuka F; Tabei K; Kobayashi E; Fukuda N; Ishimitsu T
Am J Hypertens; 2010 Sep; 23(9):1007-13. PubMed ID: 20431528
[TBL] [Abstract][Full Text] [Related]
9. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
[TBL] [Abstract][Full Text] [Related]
10. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Schafer A; Vogt C; Fraccarollo D; Widder J; Flierl U; Hildemann SK; Ertl G; Bauersachs J
J Physiol Pharmacol; 2010 Feb; 61(1):45-52. PubMed ID: 20228414
[TBL] [Abstract][Full Text] [Related]
12. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis.
Leonelli E; Bianchi R; Cavaletti G; Caruso D; Crippa D; Garcia-Segura LM; Lauria G; Magnaghi V; Roglio I; Melcangi RC
Neuroscience; 2007 Feb; 144(4):1293-304. PubMed ID: 17187935
[TBL] [Abstract][Full Text] [Related]
13. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
Dorenkamp M; Riad A; Stiehl S; Spillmann F; Westermann D; Du J; Pauschinger M; Noutsias M; Adams V; Schultheiss HP; Tschöpe C
Eur J Pharmacol; 2005 Sep; 520(1-3):179-87. PubMed ID: 16139267
[TBL] [Abstract][Full Text] [Related]
14. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Motawi TK; El-Maraghy SA; Senousy MA
J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
[TBL] [Abstract][Full Text] [Related]
16. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
17. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
18. Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
Naruse M; Tanabe A; Hara Y; Takagi S; Imaki T; Takano K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S1-3. PubMed ID: 15838251
[TBL] [Abstract][Full Text] [Related]
19. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats.
Sugimoto K; Kojima K; Baba M; Yasujima M
J Hypertens; 2011 Jul; 29(7):1337-46. PubMed ID: 21602711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
